Skip to main content
15 May, 2024

Hyris signs a distribution agreement with GrowBIGogh

Hyris signed a distribution agreement with GrowBIGogh a a company selling technology solutions for hydroponics and farming industries, based in Gilroy & Salinas, CA.

The agreement provides for the distribution of the Hyris System by GrowBIGogh in the United States for testing in private companies, laboratories and clinics, and public entities operating in the Cannabis and Plants Health business.

The US Cannabis market is projected to reach US$42.98bn in 2024 (Source: Statista Market Insights).
The Cannabis market covers products derived from the cannabis plant used for medical or recreational purposes. The market includes Medical, Pharmaceutical, and Recreational Cannabis as well as CBD Products. The Medical and Pharmaceutical Cannabis markets include products used to treat conditions such as chronic pain, mental disorders, and other medical conditions. The Recreational Cannabis and the the CBD Products markets include products used for personal enjoyment or leisure purposes.

GrowBIGogh will distribute in United States, in conjunction with Hyris System, a set of molecular testing kits to support cannabis growers in maximising productivity and minimising inefficiencies. The unique characteristics of Hyris System as smart, portable and easy genetic testing solution, make this proposition viable for a larger set of users.  

"This agreement follows Hyris mission to ease the access to genetic testing for a growing number of users and contexts" says Lorenzo Colombo, CTO at Hyris. "It is a demonstration of the recognised performances of Hyris technological solutions in various business segments and our ability to support key players in their field of activity".

 

Contact a Hyris expert to discover how to perform beyond your current genetic testing capability at This email address is being protected from spambots. You need JavaScript enabled to view it..

 

  • Hyris signs a distribution agreement with GrowBIGogh

  • Hyris technology supports the fight against one of the world’s deadliest diseases, malaria.

  • Hyris fulfils its integration into Ulisse Biomed to give birth to a new international group ready to make its mark in the global biotech market.

  • Distribution agreement renewal with Biomol Laboratories, fostering the partnership in the field of personalised medicine

  • Hyris' signed a binding agreement for a reverse take-over, leading to a new integrated entity with Ulisse Biomed

  • Hyris' new onboarding programs support researchers and developers to launch testing kits.

  • Hyris Founder&CEO Stefano Lo Priore interviewed by Carter&Benson

  • Hyris and Singlabs signed a distributorship agreement for Singapore

  • Hyris and P.Intertrade Equipments signed a distributorship agreement for Thai market.

  • Hyris to participate to SIBioC 2022 in Genova, presenting Hyris marketplace approach for laboratory medicine